NDAORALCAPSULE
Approved
Jun 1979
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
SURMONTIL (trimipramine maleate) by Teva is clinical pharmacology trimipramine capsules are an antidepressant with an anxiety-reducing sedative component to its action. First approved in 1979.
Drug data last refreshed 3d ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SURMONTIL (trimipramine maleate) is an oral tricyclic antidepressant capsule approved in 1979 that combines antidepressant efficacy with anxiety-reducing and sedative properties. The mechanism of action involves modulation of central nervous system function through pathways distinct from monoamine oxidase inhibition or stimulant-type mechanisms. Pharmacokinetics show no clinically relevant age or gender differences.
LOE Approaching
Competitive pressure remains moderate (30/100 intensity), signaling a niche but stable market position with likely constrained team scaling.
Mechanism of Action
CLINICAL PHARMACOLOGY Trimipramine capsules are an antidepressant with an anxiety-reducing sedative component to its action. The mode of action of trimipramine capsules on the central nervous system is not known. However, unlike amphetamine-type compounds it does not act primarily by stimulation of…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on SURMONTIL offers limited growth trajectory but provides stable, defensive brand management experience in a mature CNS therapeutic category. Roles focus on market retention, compliance, and relationship stewardship rather than innovation or expansion.
Brand Manager (defensive)
Worked on SURMONTIL at Teva? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.